Neurofibromatosis 2 Clinical Trial
Official title:
Resiliency Training for Patients With Neurofibromatosis Via Videoconferencing With Skype
This study tests the efficacy of an 8-week, Skype-based, group resiliency training
intervention (The Relaxation Response Resiliency Program) for improving psychological stress
in patients with Neurofibromatosis. A control group will receive a general health education
curriculum. The investigators hypothesize that patients will improve on measures of
psychological stress as a result of the resiliency program.
A substudy (Unique Protocol ID: 2013P002605b) has been approved to test this study on a
sub-population: patients with NF2 who are hard of hearing.
n/a
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Supportive Care
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03617276 -
Reliability of Functional Outcome Measures in Neurofibromatosis 2
|
||
| Active, not recruiting |
NCT00973739 -
Lapatinib Study for Children and Adults With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors
|
Phase 2 | |
| Completed |
NCT00030043 -
An Implant for Hearing Loss Due to Removal of Neurofibromatosis 2 Tumors
|
Phase 1 | |
| Recruiting |
NCT05685836 -
89Zr-Bevacizumab PET/CT Imaging in NF2 Patients
|
||
| Completed |
NCT00004437 -
Phase II Study of the Multichannel Auditory Brain Stem Implant for Deafness Following Surgery for Neurofibromatosis 2
|
Phase 2 | |
| Recruiting |
NCT03406208 -
Resiliency Training for Adults With Neurofibromatosis Via Live Videoconferencing
|
N/A | |
| Active, not recruiting |
NCT03095248 -
Trial of Selumetinib in Patients With Neurofibromatosis Type II Related Tumors
|
Phase 2 | |
| Recruiting |
NCT01885767 -
Neurofibromatosis (NF) Registry Portal
|
||
| Completed |
NCT00863122 -
Concentration and Activity of Lapatinib in Vestibular Schwannomas
|
Early Phase 1 | |
| Recruiting |
NCT03079999 -
Study of Aspirin in Patients With Vestibular Schwannoma
|
Phase 2 | |
| Terminated |
NCT00911248 -
PTC299 for Treatment of Neurofibromatosis Type 2
|
Phase 2 | |
| Completed |
NCT02811718 -
Resiliency Training for Patients With NF2 Via Videoconferencing With Skype
|
N/A | |
| Enrolling by invitation |
NCT04890132 -
Vestibular Precision: Physiology & Pathophysiology
|
N/A | |
| Completed |
NCT01490476 -
Efficacy and Safety Study of RAD001 in the Growth of the Vestibular Schwannoma(s) in Neurofibromatosis 2 (NF2) Patients
|
Phase 2 | |
| Active, not recruiting |
NCT00004483 -
NF2 Natural History Consortium
|
N/A | |
| Recruiting |
NCT03893643 -
Cutaneous and Mucosal Manifestations of Neurofribromatosis Type 2 in Children Under 15
|
||
| Active, not recruiting |
NCT04283669 -
Phase 2 Clinical Trial of Crizotinib for Children and Adults With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas
|
Phase 2 | |
| Completed |
NCT02831257 -
AZD2014 In NF2 Patients With Progressive or Symptomatic Meningiomas
|
Phase 2 |